Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00546624 |
This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Condition | Intervention | Phase |
---|---|---|
Anxiety Disorder |
Drug: MK0777 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2007_632 |
Study First Received: | October 17, 2007 |
Last Updated: | October 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00546624 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Lorazepam Anxiety Disorders Mental Disorders |
Anxiety Disorders Mental Disorders |